Skip to main content
Clinical Trials/NCT03311425
NCT03311425
Completed
Phase 3

The Effects of Intraoperative Local and Systemic Corticosteroid Administration on Postoperative Dysphagia After Anterior Cervical Fusion

Rush University Medical Center0 sites140 target enrollmentAugust 1, 2014

Overview

Phase
Phase 3
Intervention
Methylprednisolone
Conditions
Dysphagia
Sponsor
Rush University Medical Center
Enrollment
140
Primary Endpoint
Change from baseline SWAL-QOL survey at 3 months
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

The purpose of this study is to determine if the incidence and duration of postoperative dysphagia are improved in the participants receiving a local injection of methylprednisolone with systemic dexamethasone when compared to those receiving the usual systemic dexamethasone.

Detailed Description

Postoperative dysphagia is a known complication of anterior cervical spinal fusion (ACF) surgery with a published incidence that ranges from 1.7% to 50.3%.1-9 The pathophysiology of post-operative dysphagia is not fully understood and is subject to further study. Postoperative dysphagia has been reported to improve with time with a mean incidence of 19.8% at 6 months, 16.8% at 12 months, and 12.9% at 24 months after ACDF. The investigator's standard of practice is to provide 10mg of dexamethasone IV intraoperatively in order to reduce postoperative prevertebral soft tissue swelling. Despite the growing popularity of ACDF procedures, there is a lack of clear evidence supporting the utilization of perioperative corticosteroids in the setting of an ACDF.

Registry
clinicaltrials.gov
Start Date
August 1, 2014
End Date
July 20, 2019
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Kern Singh

Professor of Orthopaedic Surgery

Rush University Medical Center

Eligibility Criteria

Inclusion Criteria

  • Patients undergoing a primary 1- to 3-level ACDF:
  • (a) Diagnosis: myelopathy, radiculopathy, myeloradiculopathy, stenosis, herniated nucleus pulposus, degenerative disc disease, spondylosis, osteophytic complexes, and foraminal stenosis
  • Patients able to provide informed consent

Exclusion Criteria

  • Allergies or other contraindications to medicines in the protocol including:
  • (a) Existing history gastrointestinal bleeding
  • Existing history of dysphagia
  • Current Smokers
  • Cervical spine trauma

Arms & Interventions

Local Depomedrol plus IV dexamethasone

Local intraoperative application of methylprednisolone (Depomedrol) plus standard systemic (IV) dexamethasone

Intervention: Methylprednisolone

Local Depomedrol plus IV dexamethasone

Local intraoperative application of methylprednisolone (Depomedrol) plus standard systemic (IV) dexamethasone

Intervention: Dexamethasone

IV dexamethasone

Intraoperative systemic (IV) steroid (dexamethasone) only.

Intervention: Dexamethasone

Outcomes

Primary Outcomes

Change from baseline SWAL-QOL survey at 3 months

Time Frame: 3 months

In the postoperative period, patients will be asked to complete the SWAL-QOL survey at the 3 month follow up office visit. This will be compared to preoperative scores. Each survey is scored out of 100 with minimum score of 20 indicating severe dysphagia and 100 indicating no dysphagia/normal swallowing. As such, a greater decrease in SWAL-QOL score from preoperative (baseline) to 3 month visit indicates greater postoperative swallowing difficulty.

Secondary Outcomes

  • Change from Baseline Prevertebral Soft Tissue Swelling at 3 months(3 months)
  • Adverse Events(1 year)

Similar Trials